Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NXL

Nexalin Technology Inc

Apr 26 • 04:00PM ET

1.44

Dollar change +0.06
Percentage change 3.97	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	20.63%	Shs Outstand	7.44M	Perf Week	0.70%
Market Cap	10.71M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.90M	Perf Month	84.62%
Income	-4.65M	PEG	-	EPS next Q	-	Inst Own	0.65%	Short Float	5.55%	Perf Quarter	310.72%
Sales	0.11M	P/S	97.40	EPS this Y	-	Inst Trans	-	Short Ratio	0.40	Perf Half Y	394.85%
Book/sh	0.43	P/B	3.34	EPS next Y	-	ROA	-84.03%	Short Interest	0.33M	Perf Year	71.43%
Cash/sh	0.40	P/C	3.63	EPS next 5Y	-	ROE	-107.05%	52W Range	0.25 - 3.40	Perf YTD	255.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	2.43%	ROI	-144.97%	52W High	-57.65%	Beta	6.05
Dividend TTM	-	Quick Ratio	7.70	Sales past 5Y	175.50%	Gross Margin	-1176.40%	52W Low	469.62%	ATR (14)	0.37
Dividend Ex-Date	Mar 23, 2007	Current Ratio	8.07	EPS Y/Y TTM	-170.44%	Oper. Margin	-5143.43%	RSI (14)	48.53	Volatility	14.38% 39.72%
Employees	6	Debt/Eq	0.00	Sales Y/Y TTM	-91.62%	Profit Margin	-4197.52%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-4.90%	Payout	-	Rel Volume	0.09	Prev Close	1.38
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-46.55%	Earnings	-	Avg Volume	811.92K	Price	1.44
SMA20	-26.06%	SMA50	39.93%	SMA200	138.27%	Trades		Volume	72,601	Change	3.97%

Apr-25-24 10:44AM	Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements (GlobeNewswire)
Apr-10-24 08:30AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire)
Apr-09-24 08:30AM	Nexalin Technology Accelerates Manufacturing of its HALO Clarity Following Successful Usability, Feasibility, and Electrical Testing (GlobeNewswire)
Apr-04-24 01:00PM	Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity , a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device (GlobeNewswire) -10.42%
11:05AM	Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device (News Direct)
08:30AM	Loading…
Apr-02-24 08:30AM	Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board (GlobeNewswire) +51.05%
Mar-28-24 08:30AM	Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego (GlobeNewswire) +79.49%
Mar-14-24 08:30AM	Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin's Technology (GlobeNewswire) +20.00%
Mar-13-24 08:30AM	Nexalin Technology Announces Poster Presentation at State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment (GlobeNewswire) +8.17%
Mar-06-24 08:30AM	Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia (GlobeNewswire) +49.55%
Feb-08-24 08:30AM	Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device (GlobeNewswire)
Jan-23-24 08:30AM	Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System (GlobeNewswire)
Jan-11-24 08:30AM	Nexalin Technology Unveils Next-Generation HALO Clarity (GlobeNewswire) +9.67%
Dec-18-23 08:30AM	Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression (GlobeNewswire)
Oct-25-23 08:30AM	Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter (GlobeNewswire) +19.30%
08:30AM	Loading…
Oct-16-23 08:30AM	Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin's Neurostimulation Device to Penetrate Deep Brain Structures (GlobeNewswire) -28.92%
Aug-07-23 08:30AM	Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms (GlobeNewswire)
Aug-03-23 08:30AM	Nexalins CEO Mark White to be Interviewed Live on The Big Biz Show Today at 3PM Eastern Time (GlobeNewswire)
Jul-26-23 08:30AM	Nexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies (GlobeNewswire)
Jul-10-23 08:30AM	Nexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury (GlobeNewswire)
Jun-01-23 08:30AM	Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalins tACS Devices in the Asia Pacific Region (GlobeNewswire) +7.24%
Mar-30-23 06:33AM	Nexalin Technology Full Year 2022 Earnings: US$0.30 loss per share (vs US$1.43 loss in FY 2021) (Simply Wall St.)
Mar-27-23 07:00AM	Nexalin Technology Provides 2022 Year-End Business Update (GlobeNewswire) -18.03%
Jan-24-23 08:30AM	Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory (GlobeNewswire)
Jan-05-23 08:30AM	Nexalin Technology CEO Provides Letter to Shareholders (GlobeNewswire)
Nov-14-22 02:00PM	Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder (GlobeNewswire)
Sep-20-22 01:12PM	Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering (GlobeNewswire) -5.33%
Sep-15-22 08:54PM	Nexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering (GlobeNewswire)
Apr-10-22 06:52PM	What Kind Of Investors Own Most Of Nuix Limited (ASX:NXL)? (Simply Wall St.)

Nexalin Technology, Inc. designs and develops neurostimulation products. Its medical devices helps people with mental health illness. The company was founded by John Patrick Claude on October 19, 2010 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXL

Nexalin Technology Inc

Upgrade your FINVIZ experience